Funding for this research was provided by:
National Institutes of Health (CDP SPORE P50CA127001-07, R21CA226301, SPORE 2P50CA127001-11A1)
American Cancer Society (RSG-15-145-01-CDD)
National Comprehensive Cancer Network (YIA170032)
Elsa U. Pardee Foundation (NA)
Cancer Prevention and Research Institute of Texas (RP170067)
Uncle Kory Foundation (NA)
The Larry Deaven Fellowship (NA)
Received: 7 December 2020
Accepted: 18 April 2021
First Online: 25 June 2021
: All animal (mice) involving experiments were approved by MD Andersons’s Institutional Animal Care and Use Committee (IACUC).
: All authors give consent for publication of the manuscript.
: The authors declare no competing financial interests. F.L.M. is an inventor on a patent covering the concept of targeting ENO1-deleted tumors with inhibitors of ENO2 (US patent 9,452,182 B2) and an inventor on a patent application describing the synthesis and utility of novel pro-drug inhibitors of enolase US 62/797,315 (filed Jan. 27, 2019). F.L.M. and Y-H.L. are inventors on a patent application for the use of enolase inhibitors for the treatment of ENO1-deleted tumors (US patent 10,363,261 B2).